MC2-03 PAD™ Eye Drop
Sjogren Syndrome Dry Eye

About Dry Eye Disease (DED)
Dry eye disease is one of the most prevalent ocular diseases affecting 7% to 30% of the population depending on geography. In the US, prevalence estimates of dry eye range from 5% to 34% in individuals over 50 years old.

It is often chronic and can worsen, progressing to moderate to severe dry eye. Dry eye, in its moderate to severe form, is a multifactorial disorder caused by inflammation of the ocular surface that result in symptoms of discomfort such as eye dryness, overall eye discomfort, stinging, burning, a gritty feeling or fluctuating blurry vision. Known risk factors for dry eye include female sex, increasing age, and certain comorbid conditions such as autoimmune diseases and medications.

In Sjogren’s Disease, the mucous membranes and moisture-secreting glands of the eyes and mouth are usually affected first, resulting in decreased tears and saliva. Incidence rates show that Sjogren’s Disease is affecting 0.5% to 1.0% of the population. Most symptoms usually appear between the ages of 45 and 55 and about half of patients also have rheumatoid arthritis or other connective tissue diseases, such as lupus.

Aim of MC2-03
Ciclosporin is widely used as a therapeutic agent in eye drops for treatment of patients with moderate to severe dry eye. Current formulations for treatment of patients with moderate to severe dry eye have sub-optimal efficacy profiles and may cause stinging and burning in the eyes of patients.

Using PAD Technology™ we have developed a new PAD based eye drop formulation designed to improve delivery of the active ingredient to ocular surface tissues and conjunctiva to reduce inflammation without causing stinging and burning in the eyes.

MC2-03 has the potential to be first therapy for treatment of Sjogren dry eye disease. A treatment intended to significantly improve the daily quality of life of patients and provide an attractive value proposition to multiple stakeholders such as patients, physicians, and societies.

Clinical Stage
Phase 2 (n=265) successfully completed. Phase 3 in planning for H2 2022.

MC2-03 PAD Eye Drop
Active ingredient: Ciclosporin
Indication: Sjogren Syndrome – moderate to severe dry eye

Pipeline